Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15037MR)

This product GTTS-WQ15037MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15037MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13881MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ9771MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ11717MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ1232MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ11574MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ12230MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ2638MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ4713MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986168
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW